ProSciento, Inc and Antaros Medical recently announced a strategic collaboration to study the action of cardiometabolic drugs and drug candidates using PET/MRI imaging. The initiative will focus on diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH).
